Skip to main content
Top
Published in: BMC Gastroenterology 1/2022

Open Access 01-12-2022 | Fatty Liver | Research article

The prevalence of alcoholic and nonalcoholic fatty liver disease in adolescents and young adults in the United States: analysis of the NHANES database

Authors: Naim Alkhouri, Ashraf Almomani, Phuc Le, Julia Y. Payne, Imad Asaad, Celine Sakkal, Miriam Vos, Mazen Noureddin, Prabhat Kumar

Published in: BMC Gastroenterology | Issue 1/2022

Login to get access

Abstract

Background

The prevalence of fatty liver disease is potentially increasing in adolescents and young adults (AYAs) due to the obesity and alcohol pandemics. The aim of this study was to assess the prevalence of alcohol-associated fatty liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD) in a representative U.S. cohort utilizing transient elastography to directly measure hepatic steatosis and suspected fibrosis.

Methods

AYAs (age 15–39 years) with valid FibroScan® measurements in the National Health and Nutrition Examination Survey (NHANES) database (2017–2018) were included in the analyses. Those with viral hepatitis, pregnancy, or ALT/AST > 500 U/L were excluded. The population was divided into those with excessive alcohol consumption (ALQ130) and those without. Controlled attenuation parameter (CAP) score ≥ 248 dB/m was used to identify suspected ALD and NAFLD. In those with evidence of ALD, the following cutoffs of liver stiffness measurement (LSM) were used for suspected fibrosis: F ≥ F2 at LSM ≥ 7.5 kPa and F ≥ F3 at ≥ 9.5 kPa, respectively. In those with suspected NAFLD, the following LSM cutoffs were used: F ≥ F2 at 6.1 and F ≥ F3 at ≥ 7.1, respectively. Cutoffs were chosen based on published literature to maximize sensitivity.

Results

Comparing to those without, subjects with excessive alcohol consumption tended to be older (29.8 vs 28.5 years), have a higher BMI (29.3 vs 28.9 kg/m2), and be from a White ethnicity (65.3% vs. 55.4%). In subjects with excessive alcohol consumption, suspected ALD was present in 56.59% (95% CI 41.57–70.49). In those with suspected ALD, suspected significant fibrosis (F ≥ F2) was present in 12.3% (95% CI 4.74–28.34) and advanced fibrosis (F ≥ F3) was present in 6.31% (95% CI 0.69–39.55). Similarly, in subjects without excessive alcohol consumption, suspected NAFLD was present in 40.04% (36.64–43.54). In those with suspected NAFLD, suspected significant fibrosis (F ≥ F2) was present in 31.07% (27.25–35.16) and suspected advanced fibrosis (F ≥ F3) was present in 20.15% (16.05–24.99).

Conclusion

A significant percentage of AYAs are at risk for ALD and NAFLD and a subset of these subjects is at risk for significant fibrosis. Efforts should focus on increasing awareness of the prevalence of ALD and NAFLD in this population and to mitigate modifiable risk factors.
Appendix
Available only for authorised users
Literature
2.
go back to reference Wong RJ, Liu B, Bhuket T. Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a crosssectional analysis of 2011–2014 National Health and Nutrition Examination Survey. Aliment Pharmacol Ther. 2017;46:974–80.CrossRef Wong RJ, Liu B, Bhuket T. Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a crosssectional analysis of 2011–2014 National Health and Nutrition Examination Survey. Aliment Pharmacol Ther. 2017;46:974–80.CrossRef
6.
go back to reference Wieland AC, Mettler P, McDermott MT, Crane LA, Cicutto LC, Bambha KM. Low awareness of nonalcoholic fatty liver disease among patients at high metabolic risk. J Clin Gastroenterol. 2015;49:e6–10.CrossRef Wieland AC, Mettler P, McDermott MT, Crane LA, Cicutto LC, Bambha KM. Low awareness of nonalcoholic fatty liver disease among patients at high metabolic risk. J Clin Gastroenterol. 2015;49:e6–10.CrossRef
7.
go back to reference Mozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999–2006. Diabetes Care. 2011;34:216–9.CrossRef Mozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999–2006. Diabetes Care. 2011;34:216–9.CrossRef
8.
go back to reference WHO. Global status report on alcohol and health 2018. Geneva: World Health Organization; 2018. WHO. Global status report on alcohol and health 2018. Geneva: World Health Organization; 2018.
16.
go back to reference Chamorro A, Torres J, Mirón-Canelo J, González-Sarmiento R, Laso F, Marcos M. Systematic review with meta-analysis: the I148M variant of patatin-like phospholipase domain-containing 3 gene (PNPLA3) is significantly associated with alcoholic liver cirrhosis. Aliment Pharmacol Therap. 2014;40(6):571–81. https://doi.org/10.1111/apt.12890.CrossRef Chamorro A, Torres J, Mirón-Canelo J, González-Sarmiento R, Laso F, Marcos M. Systematic review with meta-analysis: the I148M variant of patatin-like phospholipase domain-containing 3 gene (PNPLA3) is significantly associated with alcoholic liver cirrhosis. Aliment Pharmacol Therap. 2014;40(6):571–81. https://​doi.​org/​10.​1111/​apt.​12890.CrossRef
19.
go back to reference National Center for Health Statistics (US). Health, United States, 2018. Hyattsville, MD: National Center for Health Statistics (US); 2019. National Center for Health Statistics (US). Health, United States, 2018. Hyattsville, MD: National Center for Health Statistics (US); 2019.
20.
go back to reference Karlas T, Petroff D, Sasso M, Fan J, Mi Y, De Lédinghen V, Kumar M, Lupsor-Platon M, Han K, Cardoso AC, Ferraioli G, Chan W, Wong VW, Myers RP, Chayama K, Friedrich-Rust M, Beaugrand M, Shen F, Hiriart J, Sarin SK, Badea R, Jung KS, Marcellin P, Filice C, Mahadeva S, Wong GL-H, Crotty P, Masaki K, Bojunga J, Bedossa P, Keim V, Wiegand J. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022–30. https://doi.org/10.1016/j.jhep.2016.12.022. CrossRefPubMed Karlas T, Petroff D, Sasso M, Fan J, Mi Y, De Lédinghen V, Kumar M, Lupsor-Platon M, Han K, Cardoso AC, Ferraioli G, Chan W, Wong VW, Myers RP, Chayama K, Friedrich-Rust M, Beaugrand M, Shen F, Hiriart J, Sarin SK, Badea R, Jung KS, Marcellin P, Filice C, Mahadeva S, Wong GL-H, Crotty P, Masaki K, Bojunga J, Bedossa P, Keim V, Wiegand J. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022–30. https://​doi.​org/​10.​1016/​j.​jhep.​2016.​12.​022. CrossRefPubMed
23.
go back to reference Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005–23. https://doi.org/10.1002/hep.25762.CrossRefPubMed Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005–23. https://​doi.​org/​10.​1002/​hep.​25762.CrossRefPubMed
29.
go back to reference Williams R, Alexander G, Armstrong I, Baker A, Bhala N, Camps-Walsh G, Cramp ME, Lusignan S, Day N, Dhawan A, Dillon J, Drummond C, Dyson J, Foster G, Gilmore I, Hudson M, Kelly D, Langford A, McDougall N, Meier P, Moriarty K, Newsome P, O’Grady J, Pryke R, Rolfe L, Rice P, Rutter H, Sheron N, Taylor A, Thompson J, Thorburn D, Verne J, Wass J, Yeoman A. Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: Fourth report of the Lancet standing Commission on liver disease in the UK. Lancet. 2018;391(10125):1097–107. https://doi.org/10.1016/s0140-6736(17)32866-0.CrossRefPubMed Williams R, Alexander G, Armstrong I, Baker A, Bhala N, Camps-Walsh G, Cramp ME, Lusignan S, Day N, Dhawan A, Dillon J, Drummond C, Dyson J, Foster G, Gilmore I, Hudson M, Kelly D, Langford A, McDougall N, Meier P, Moriarty K, Newsome P, O’Grady J, Pryke R, Rolfe L, Rice P, Rutter H, Sheron N, Taylor A, Thompson J, Thorburn D, Verne J, Wass J, Yeoman A. Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: Fourth report of the Lancet standing Commission on liver disease in the UK. Lancet. 2018;391(10125):1097–107. https://​doi.​org/​10.​1016/​s0140-6736(17)32866-0.CrossRefPubMed
37.
go back to reference Wong VW, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B, Choi PC, Kowo M, Chan AW, Merrouche W, Sung JJ, De Lédinghen V. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2009;51(2):454–62. https://doi.org/10.1002/hep.23312.CrossRef Wong VW, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B, Choi PC, Kowo M, Chan AW, Merrouche W, Sung JJ, De Lédinghen V. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2009;51(2):454–62. https://​doi.​org/​10.​1002/​hep.​23312.CrossRef
41.
go back to reference Newsome PN, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan W, Yilmaz Y, Czernichow S, Zheng M, Wong VW, Allison M, Tsochatzis E, Anstee QM, Sheridan DA, Eddowes PJ, Guha IN, Cobbold JF, Paradis V, Bedossa P, Miette V, Fournier-Poizat C, Sandrin L, Harrison SA, Harrison SA. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: A prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5(4):362–73. https://doi.org/10.1016/s2468-1253(19)30383-8.CrossRefPubMedPubMedCentral Newsome PN, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan W, Yilmaz Y, Czernichow S, Zheng M, Wong VW, Allison M, Tsochatzis E, Anstee QM, Sheridan DA, Eddowes PJ, Guha IN, Cobbold JF, Paradis V, Bedossa P, Miette V, Fournier-Poizat C, Sandrin L, Harrison SA, Harrison SA. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: A prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5(4):362–73. https://​doi.​org/​10.​1016/​s2468-1253(19)30383-8.CrossRefPubMedPubMedCentral
44.
45.
go back to reference Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, Guha IN, Cobbold JF, Deeks JJ, Paradis V, Bedossa P, Newsome PN. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(6):1717–30. https://doi.org/10.1053/j.gastro.2019.01.042.CrossRefPubMed Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, Guha IN, Cobbold JF, Deeks JJ, Paradis V, Bedossa P, Newsome PN. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(6):1717–30. https://​doi.​org/​10.​1053/​j.​gastro.​2019.​01.​042.CrossRefPubMed
48.
go back to reference Alkhouri N, Le P, Yang J, Sakkal C, Polanco P, Vos M, Noureddin M. The prevalence of alcoholic and nonalcoholic fatty liver disease in adolescents and young adults in the United States: analysis of the NHANES database. Oral Abstr Hepatol. 2021;74:1–156. https://doi.org/10.1002/hep.32187.CrossRef Alkhouri N, Le P, Yang J, Sakkal C, Polanco P, Vos M, Noureddin M. The prevalence of alcoholic and nonalcoholic fatty liver disease in adolescents and young adults in the United States: analysis of the NHANES database. Oral Abstr Hepatol. 2021;74:1–156. https://​doi.​org/​10.​1002/​hep.​32187.CrossRef
Metadata
Title
The prevalence of alcoholic and nonalcoholic fatty liver disease in adolescents and young adults in the United States: analysis of the NHANES database
Authors
Naim Alkhouri
Ashraf Almomani
Phuc Le
Julia Y. Payne
Imad Asaad
Celine Sakkal
Miriam Vos
Mazen Noureddin
Prabhat Kumar
Publication date
01-12-2022
Publisher
BioMed Central
Keyword
Fatty Liver
Published in
BMC Gastroenterology / Issue 1/2022
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-022-02430-7

Other articles of this Issue 1/2022

BMC Gastroenterology 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine